Double-Coated Dosage Form for Rapid Duodenal Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dosage forms do not effectively release biologically active ingredients in the duodenum due to a lag-time of at least 45 minutes in phosphate buffer pH 5.5, missing the pH trigger for drug release, which is crucial for duodenal ulcer treatment and systemic drug absorption.
Innovation Solution
A dosage form with a core coated by an intermediate layer containing specific release acceleration agents like iron oxide, aluminium oxide, and an enteric coating layer, designed to achieve at least 80% drug release at pH 3 to 6 within 30 minutes, using polymers with specific glass transition temperatures and coatings of 2.0 to 30 mg/cm² thickness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a conventional enteric coating is used, then the dosage form maintains enteric properties (low drug release in acidic pH), but the drug release is delayed by at least 45 minutes in phosphate buffer pH 5.5, missing the duodenal pH trigger
Solution Approach 1:
The coating system is divided into two distinct layers: an enteric coating layer (ECL) that provides pH-dependent release control, and an intermediate coating layer (ICL) containing release acceleration agents. This segmentation allows the ECL to maintain enteric properties while the ICL accelerates drug release at duodenal pH, resolving the contradiction between reliable enteric behavior and timely drug release.
Solution Approach 2:
The intermediate coating layer acts as an intermediary between the core and the enteric coating layer. It contains release acceleration agents (iron oxide, aluminium oxide, titanium dioxide, dimethyl sulfoxide, zinc oxide, sucrose, maltose, lactose, dextrates, glucose, or fructose) that facilitate faster drug release at duodenal pH without compromising the enteric properties provided by the ECL.
2Reliability
If the dosage form passes through the duodenum without drug release, then enteric protection is maintained, but the drug fails to release in the target location (duodenum) and enters the jejunum instead
Solution Approach 1:
The intermediate coating layer introduces local quality changes by containing release acceleration agents specifically in the ICL, which interact with the duodenal environment to trigger rapid drug release at the target location. This localized functionality ensures the drug releases in the duodenum rather than passing through to the jejunum, while the ECL maintains overall enteric protection.
3Reliability
If the trigger pH for duodenal release is not achieved, then the enteric coating remains intact, but the biologically active ingredient is not released as required for duodenal ulcer treatment and systemic absorption
Solution Approach 1:
The release acceleration agents in the intermediate coating layer modify the physical-chemical parameters of the coating system at duodenal pH. These agents facilitate drug release by altering coating permeability or dissipation characteristics at the target pH range, enabling efficient drug release while the enteric coating maintains its integrity in the acidic stomach environment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution ensures rapid drug release in the duodenum, enhancing duodenal ulcer treatment and systemic drug absorption by achieving at least 80% drug release within 30 minutes at pH 3 to 6, meeting USP 43 monograph requirements.
Implementation Method 1
designed to achieve at least 80% drug release at pH value 3 to 6 within 30 minutes
Implementation Method 2
at least one release acceleration agent selected from iron oxide, aluminium oxide, titanium dioxide, dimethyl sulfoxide, zinc oxide, sucrose, maltose, lactose, dextrates, glucose, fructose
Implementation Method 3
an enteric coating layer (ECL) onto or above the intermediate coating layer
Data Source
AI summary
A dosage form has a core with at least one biologically active ingredient, an intermediate coating layer (ICL), and an enteric coating layer (ECL). The ICL has at least one polymer, at least one alkaline agent, and at least one release acceleration agent. The ECL has at least one polymer. A method for obtaining the dosage form coats the ICL on the core via spray coating, followed by the coating of the ECL on the ICL via spray coating. The dosage form provides accelerated drug release at values of pH 3 to pH 6, with at least 80% drug release within 60 min at pH values 3 and 5.